GTG.AX - Genetic Technologies Limited

ASX - ASX Delayed price. Currency in AUD
0.011
0.000 (0.00%)
As of 11:23AM AEDT. Market open.
Stock chart is not supported by your current browser
Previous close0.011
Open0.011
Bid0.010 x 0
Ask0.011 x 0
Day's range0.010 - 0.011
52-week range0.007 - 0.021
Volume6,447,154
Avg. volume3,964,033
Market cap27.985M
Beta (3Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)-0.002
Earnings date1 Mar. 2016 - 5 Mar. 2016
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.25
  • GlobeNewswirelast month

    Genetic Technologies Invited to Establish a Market Presence in Hainan, China

    MELBOURNE, Australia, Sept. 17, 2018-- Hainan Resort Software Community has on behalf of Hainan Ecological Smart City Group formally extended an invitation to Genetic Technologies Limited to establish ...

  • GlobeNewswire2 months ago

    Genetic Technologies Limited Invited by Representatives of the Hainan Government to Discuss Market Entry into China

    MELBOURNE, Australia, Aug. 21, 2018-- Representatives of the Hainan Government- Hainan Ecological Smart City Group, a Chinese industrial park development & operations company have formally invited Genetic ...

  • GlobeNewswire2 months ago

    Genetic Technologies Announces Proposed Joint Venture with Beijing Zishan Health Consultancy Limited

    Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has signed a Heads of Agreement (Agreement) with Beijing Zishan Health Consultancy Limited (Zishan). Zishan will take on the functions of sales, account management, marketing and promotion of GTG’s genetic risk assessment products for the Chinese market.

  • GlobeNewswire2 months ago

    Genetic Technologies Secures A$20 Million Equity Placement Facility

    Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a A$20 million Equity Placement Facility (the “Facility”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment management firm, to strengthen the Company’s funding position. Under the Facility, Kentgrove Capital may provide the Company with up to A$20 million of equity capital in a series of individual placements of up to $1 million (or a higher amount by mutual agreement) over the next 20 months.

  • GlobeNewswire3 months ago

    Genetic Technologies Formalises Strategic Alliance with Blockchain Global

    Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Framework Agreement (“Agreement”) with Blockchain Global Limited ACN 601 628 497 (“BCG”).

  • GlobeNewswire3 months ago

    Genetic Technologies Announces Appointment of Swisstec as Non-Exclusive Asian Distributor

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Swisstec Health Analytics Ltd. (“Swisstec”).  This agreement grants Swisstec the right to explore opportunities to deliver GTG’s genetic screening tests to hospital networks in Asia.

  • Genetic Technologies Stock Up on Genetic Test Update
    Market Realist3 months ago

    Genetic Technologies Stock Up on Genetic Test Update

    Today, Genetic Technologies (GENE) was trading over 70% higher than yesterday’s closing price of $1.09. The stock jumped ~72.5% in premarket trading. The stock price and volumes rose on the news of the company’s on-track breast cancer and colorectal cancer risk assessment tests, slated for release in October.